ORLANDO, Florida - Asher Camp is now four and a half years old. He was diagnosed with Spinal Muscular Atrophy at just six months.
"For days we were crying, because we just knew what we were about to face," admitted his mother Amanda.
Spinal Muscular Atrophy, or SMA, is the number one genetic cause of death for infants today.
It is a disease that robs a person of their physical strength, affecting the motor nerve cells in the spinal cord.
It takes away the ability to walk, eat, and even breathe.
Without feeding tubes and other support methods, about three quarters of babies with Type One SMA die before the age of two.
"What we've learned through the clinical trials with spinraza is that definitely the drug improves both survival and the ability to improve in their motor function", said Dr. Richard Finkel, chief of Neurology at Nemours Children's Hospital.
"So what spinraza does, is it works on this SMN-2 gene to try to increase the amount of protein that's made and try to restore function," explained Dr. Finkel.
Spinraza or nusinersen was approved by the FDA in December of 2016. The results have been transformative for Asher.
"He is doing things like crawling and sitting up, he's able to balance himself while standing," said his mother.
Dr. Finkel says early diagnosis and treatment is key.
"Hopefully the word is getting out to neurologists who would be caring for these babies to say that SMA is now a treatable disease."
There seem to be no negative side effects to the drug. But, long term trials are still being conducted.
Spinraza costs about $125,000 per dose.
It is covered by most insurances and state Medicaids and must be administered by spinal tap every four months in a hospital or clinical setting.
SMA SYMPTOMS: Symptoms range from mild all the way to severe. The primary symptom is weakness of the voluntary muscles, including those closest to the center of the body; for example, shoulders, hips, thighs, and upper back. Other complications may occur when the muscles for breathing and swallowing are affected. If the muscles of the back weaken, curvatures may develop. Most infants with SMA are not expected to survive past two years of age, and if they do, it is using breathing and feeding devices for assistance. An individual with SMA may be unable to lift his head, arms or legs. He may not be able to grip things with his hands, or stretch, roll over, etc. (Source: https://www.mda.org/disease/spinal-muscular-atrophy)
If this story has impacted your life or prompted you or someone you know to seek or change treatments, please let us know by contacting Jim Mertens at firstname.lastname@example.org or Marjorie Bekaert Thomas at email@example.com.